---

---

tags : Therapy    exchanges : Nasdaq   

save search

---

Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
PSTX | News | $2.005 -1.72% -1.75% 520K |

Health Technology

| 0.0% | O: 0.25% H: 0.0% C: 0.0%
cell meeting therapeutics therapy

---

Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
Published: 2024-04-17 (Crawled : 16:00) - biospace.com/
HYPR | $0.81 -10.99% -12.35% 190K |

Manufacturing

| -8.08% | O: 0.0% H: 0.0% C: -8.08%
first alzheimer’s care enroll therapy study

---

Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
PSTX | News | $2.005 -1.72% -1.75% 520K |

Health Technology

| 0.49% | O: 0.0% H: 2.46% C: 0.49%
day pipeline therapeutics therapy

---

Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
AFMD | $5.1 -2.49% -2.55% 90K |

Health Technology

| -2.42% | O: -2.42% H: 0.0% C: 0.0%
allonk first candidate lupus cell trial therapy

---

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
LXEO | $12.1 -1.31% -1.32% 83K |

| 2.81% | O: 5.32% H: 0.0% C: -2.63%
lx2006 fda candidate granted treatment designation for therapeutics therapy

---

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
ITCI | News 0 d | $72.01 -6.1% -6.5% 4.7M |

Health Technology

| 18.82% | O: 14.75% H: 12.75% C: 6.04%
positive topline therapy results study

---

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
INCY | $52.82 0.19% 0.19% 1.8M |

Health Technology

| -1.33% | O: -0.17% H: 1.41% C: -0.22%
t-cell for therapy growth market

---

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Published: 2024-04-15 (Crawled : 14:00) - globenewswire.com
IMMX | News | $2.25 -10.0% -11.11% 190K |

| -9.42% | O: 1.09% H: 1.79% C: -4.66%
nxc-201 presentation cell biopharma for meeting therapy

---

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
CRBU | $3.91 0.0% 1.4M |

Health Technology

| -4.52% | O: -0.71% H: 5.27% C: -2.4%
presentation cell meeting therapy

---

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
Published: 2024-04-11 (Crawled : 12:00) - phiopharma.com
PHIO | $0.63 -2.93% -3.02% 62K |

Health Technology

| -4.69% | O: 3.8% H: 1.15% C: -1.19%
presentation cell pharmaceuticals meeting therapy

---

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
Published: 2024-04-10 (Crawled : 16:00) - globenewswire.com
ORGS | $0.5089 -5.04% 27K |

Health Technology

| 5.15% | O: 7.22% H: 69.23% C: 0.73%
partnership cell global therapy

---

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.315 -8.68% -9.51% 8M |

Health Technology

| -8.77% | O: 2.92% H: 3.41% C: 2.27%
ocu400 approval positive for therapy

---

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
INAB | $1.04 4.0% 3.85% 130K |

| -8.26% | O: 6.42% H: 1.72% C: -5.17%
cell preclinical for therapy platform

---

Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
Published: 2024-04-09 (Crawled : 13:00) - globenewswire.com
NUWE | $0.262 -5.69% -6.03% 530K |

Manufacturing

| -27.27% | O: 3.84% H: 0.0% C: -3.05%
smartflow aquadex health system ford therapy

---

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.16 -2.26% -2.31% 17K |

Health Technology

| -25.34% | O: 2.36% H: 6.6% C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy

---

GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 11:00) - prnewswire.com
VSTM | $10.19 -6.0% -6.38% 67K |

Health Technology

| -5.29% | O: 5.64% H: 1.41% C: -2.89%
gfh375 meeting therapeutics potential therapy

---

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Published: 2024-04-08 (Crawled : 00:00) - biospace.com/
PSTX | News | $2.005 -1.72% -1.75% 520K |

Health Technology

| -31.77% | O: -0.67% H: 0.0% C: 0.0%
car-t therapeutics potential therapy

---

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
IPSC | $2.97 4.58% 4.38% 150K |

Professional, Scientific, and T...

| -24.87% | O: -1.59% H: 8.87% C: 7.8%
association cancer cell research preclinical for meeting technology therapeutics therapy platform

---

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.315 -8.68% -9.51% 8M |

Health Technology

| -1.89% | O: 26.42% H: 3.48% C: -6.47%
ocu400 fda first clearance trial therapy

---

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Published: 2024-04-06 (Crawled : 20:20) - globenewswire.com
NVSEF | $93.6375 6.88% 82K |

Health Technology

| Email alert Add to watchlist
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| Email alert Add to watchlist
leqvio novartis therapy show

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---